GHK-Cu is one of the most extensively studied regenerative peptides on the planet, backed by over 40 years of peer-reviewed research and thousands of published studies

Individuals with any of the following conditions should consult with their healthcare provider before use and may not be eligible for treatment: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Known hypersensitivity to GLP-1 or GLP-1/GIP medications or any formulation components, including additives such as vitamin B12 or cobalt Pregnancy or plans to become pregnant (therapy should be discontinued at least two months prior to planned pregnancy) Diabetic ketoacidosis (DKA) or type 1 diabetes Severe gastrointestinal disease (including gastroparesis or active inflammatory bowel disease) Severe cardiovascular disease (including unstable coronary artery disease or heart failure) Recent bariatric or gastrointestinal surgery within the past six months Active cancer currently undergoing chemotherapy or radiation treatment This list is not comprehensive

It is frequently administered by intramuscular, intra-articular, or soft tissue injection, providing targeted relief for numerous acute and chronic conditions
BPC-157, used rigorously and within the limits of current evidence, is one of the more interesting tools available for addressing that decline at a mechanistic level
While not classified as a controlled substance, it is regulated differently for research, therapeutic, and athletic contexts
Figure 2: Time spent in the target quadrant by test subjects in each experimental treatment group